Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-09 04:14 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Not applicableCompletedINTERVENTIONAL

Semi-quantitative Pregnancy Test to Monitor hCG Levels After Assisted Fertility Treatment

ClinicalTrials.gov · NCT01919502 · Registry updated: 2014-05-14

Condition / research focus: Embryo Transfer; Intrauterine Insemination (IUI)
Sponsor: Gynuity Health Projects
Countries with listed sites: United States
Registry dates and results: Start: 2013-10. Completion: 2014-04 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semi-quantitative urine pregnancy test (device) — also listed as: Quanti5 Multilevel hCG Pregnancy Test

Where the study takes place — 1 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Stanford University Medical Center
Palo Alto, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Effectiveness of Pregnancy Tests as an Assessment Tool to Identify Continuing Pregnancy

ClinicalTrials.gov · NCT01856777 · Registry updated: 2014-05-14

Condition / research focus: Medical Abortion
Sponsor: Gynuity Health Projects
Countries with listed sites: Vietnam
Registry dates and results: Start: 2013-06. Completion: 2014-02 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semi-quantitative panel test (device) — also listed as: dBest (AmeriTek, Seattle WA, USA)
High sensitivity urine pregnancy test (device) — also listed as: Quickstick one-step hCG Pregnancy Test, Phamatech, San Diego, CA, USA

Where the study takes place — 2 listed sites

Hocmon General District Hospital
Hochiminh City, Vietnam
Site recruitment: Not reported
Hungvuong Hospital
Hochiminh City, Vietnam
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Validation of the Respirio Flu Test for the Rapid Identification of Influenza A/B

ClinicalTrials.gov · NCT01431768 · Registry updated: 2014-04-30

Condition / research focus: Influenza
Sponsor: Respirio Pty Ltd
Countries with listed sites: Australia
Registry dates and results: Start: 2011-07. Completion: 2012-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Respirio Flu Test (device)

Where the study takes place — 2 listed sites

Taringa 7 Day Medical Practice
Brisbane, Queensland, Australia
Site recruitment: Not reported
Capalaba Medical Centre
Brisbane, Queensland, Australia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Comparing the Efficacy of Urinary and Recombinant Human Chorionic Gonadotropin (hCG) on Oocyte Maturity

ClinicalTrials.gov · NCT01507376 · Registry updated: 2014-04-25

Condition / research focus: In Vitro Fertilization
Sponsor: Royan Institute
Countries with listed sites: Iran
Registry dates and results: Start: 2010-10. Completion: 2013-06 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

recombinant hCG (drug)
recombinant hCG (drug)
urinary hCG (drug)

Where the study takes place — 1 listed sites

Royan Institute
Tehran, Iran
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Live Birth After Fresh Embryo Transfer Vs Frozen-thawed Embryo Transfer in Women With Polycystic Ovary Syndrome

ClinicalTrials.gov · NCT01841528 · Registry updated: 2014-04-16

Condition / research focus: Polycystic Ovary Syndrome; Infertility
Sponsor: Zi-jiang Chen
Countries with listed sites: China
Registry dates and results: Start: 2013-06. Completion: 2015-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

fresh embryo transfer (other)
frozen-thawed embryo transfer (other)

Where the study takes place — 14 listed sites

The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
Site recruitment: Not reported
The First Affiliated Hospital of Lanzhou University
Lanzhou, Gansu, China
Site recruitment: Not reported
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, China
Site recruitment: Not reported
The sixth Affiliated Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, China
Site recruitment: Not reported
Guangxi Maternal and Child Health Hospital
Nanning, Guangxi, China
Site recruitment: Not reported
Renmin Hospital of Wuhan University
Wuhan, Hubei, China
Site recruitment: Not reported
Jiangsu Province Hospital
Nanjing, Jiangsu, China
Site recruitment: Not reported
Jiangxi Maternal and Child Health Hospital
Nanchang, Jiangxi, China
Site recruitment: Not reported
Reproductive Medicine Center in Shenyang City
Shenyang, Liaoning, China
Site recruitment: Not reported
Reproductive medical hospital affiliated to Shandong University
Jinan, Shandong, China
Site recruitment: Not reported
Yuhuangding Hospital in Yantai
Yantai, Shandong, China
Site recruitment: Not reported
Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Shanxi Provincial Maternity and Children's Hospital
Xi’an, Shanxi, China
Site recruitment: Not reported
Sir Run Run Shaw Hospital
Hangzhou, Zhejiang, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

A Study to Compare the Safety and Efficacy of Cetrotide® 3 Milligram (mg) Versus Antagon™ in Women Undergoing Ovarian Stimulation

ClinicalTrials.gov · NCT00298025 · Registry updated: 2014-03-26

Condition / research focus: Infertile Women Undergoing Assisted Reproductive Technology (ART)
Sponsor: EMD Serono
Countries with listed sites: No country reported
Registry dates and results: Start: 2003-09. Completion: 2004-05 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Cetrotide® (drug) — also listed as: Cetrorelix acetate
Antagon ™ (drug) — also listed as: Ganirelix acetate
Recombinant human follicle stimulating hormone (r-hFSH) (drug) — also listed as: Gonal-f®
Human Menopausal Gonadotropin (hMG) (drug) — also listed as: Pergonal®
Recombinant Human Choriogonadotropin (r-hCG) (drug) — also listed as: Ovidrel®, Choriogonadotropin alfa

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase not reported / not applicableTerminatedOBSERVATIONAL

Predictive Factors of Ovarian Response in Ovulation Induction With Intrauterine Insemination of a Gonal-f Low-dose Regimen

ClinicalTrials.gov · NCT01100346 · Registry updated: 2014-03-18

Condition / research focus: Infertility
Sponsor: Merck KGaA, Darmstadt, Germany
Countries with listed sites: Taiwan
Registry dates and results: Start: 2010-01. Completion: 2010-09 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Gonal-f (Follitropin alpha) (drug) — also listed as: Gonal-f

Where the study takes place — 1 listed sites

Far Eastern Memorial Hospital, No.21 Nan-Ya S. Rd., Sec.2 Pan-Chiao
Taipei, Taiwan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Progesterone Serum Levels in Subfertile Female Patients Undergoing in Vitro Fertilisation (IVF)

ClinicalTrials.gov · NCT01225835 · Registry updated: 2014-03-14

Condition / research focus: Infertility
Sponsor: Ferring Pharmaceuticals
Countries with listed sites: Germany
Registry dates and results: Start: 2010-10. Completion: 2013-06 (may be estimated). Results are posted in this registry.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Menotrophin (drug) — also listed as: Menogon® HP
Follitrophin alpha (drug) — also listed as: Gonal-f®
Cetrorelix (drug) — also listed as: Cetrotide®, GnRH antagonist
Choriongonadotropin (drug) — also listed as: Brevactid®, human chorionic gonadotropin (hCG)
Progesterone (drug) — also listed as: Crinone®, intravaginal progesterone

Where the study takes place — 8 listed sites

Fertility Center Berlin
Berlin, Germany
Site recruitment: Not reported
Praxisklinik Sydow am Gendarmenmarkt
Berlin, Germany
Site recruitment: Not reported
Kinderwunschzentrum Dortmund
Dortmund, Germany
Site recruitment: Not reported
Universitätsklinikum Duesseldorf, Frauenklinik
Düsseldorf, Germany
Site recruitment: Not reported
Praxis für Kinderwunschbehandlung
Erlangen, Germany
Site recruitment: Not reported
NOVUM Zentrum
Essen, Germany
Site recruitment: Not reported
IVF Zentrum
Saar, Germany
Site recruitment: Not reported
Endokrinologikum Ulm
Ulm, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Efficacy and Safety Study of Topical Rapamycin Associated With Pulsed Dye Laser in Patients With Sturge-Weber Syndrome

ClinicalTrials.gov · NCT02080624 · Registry updated: 2014-03-06

Condition / research focus: Sturge- Weber Syndrome
Sponsor: Clinica Universidad de Navarra, Universidad de Navarra
Countries with listed sites: Spain
Registry dates and results: Start: 2011-01. Completion: 2012-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Drug: Topical Rapamycin (drug) — also listed as: topical rapamycin 1%

Where the study takes place — 1 listed sites

Clinica Universidad de Navarra
Pamplona, Navarre, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2TerminatedINTERVENTIONAL

A Phase II Study to Assess the Efficacy and Safety of Luveris® (Lutropin Alfa) in Mid Follicular Phase for Controlled Ovarian Stimulation (COS) in Advanced Reproductive Age

ClinicalTrials.gov · NCT01079949 · Registry updated: 2014-02-27

Condition / research focus: Infertility; Ovulation Induction
Sponsor: Merck KGaA, Darmstadt, Germany
Countries with listed sites: Spain
Registry dates and results: Start: 2007-11. Completion: 2010-10 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

r-hLH + r-hFSH (drug) — also listed as: Luveris®, Lutropin alfa
r-hFSH (drug)
Recombinant Human Choriogonadotropin (r-hCG) (drug) — also listed as: Ovitrelle®
GnRH antagonist (drug) — also listed as: Cetrotide®

Where the study takes place — 1 listed sites

Instituto Marqués
Barcelona, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Long Acting FSH Plus Antagonist Versus Daily FSH Plus Antagonist Versus Short Agonist Protocol in Poor Responders Undergoing IVF

ClinicalTrials.gov · NCT02070198 · Registry updated: 2014-02-25

Condition / research focus: Female Infertility; Poor Responder
Sponsor: Bioroma
Countries with listed sites: Italy
Registry dates and results: Start: 2013-12. Completion: 2014-12 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Long acting FSH and GnRH antagonist (drug)
Daily FSH and GnRH antagonist (drug)
Triptorelin and recombinant FSH (drug)

Where the study takes place — 1 listed sites

Bioroma
Rome, Italy, Italy
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Intrauterine Injection of HCG and Implantation Rate

ClinicalTrials.gov · NCT01933126 · Registry updated: 2014-02-19

Condition / research focus: Pregnancy Rate; Implantation Rate
Sponsor: Assaf-Harofeh Medical Center
Countries with listed sites: Israel
Registry dates and results: Start: 2013-08. Completion: 2014-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

HCG injection (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Assaf Harofeh Medical Center
Be’er Ya‘aqov, Zerifin, Israel
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2TerminatedINTERVENTIONAL

AS900672-Enriched in Ovulation Induction

ClinicalTrials.gov · NCT00553514 · Registry updated: 2014-02-13

Condition / research focus: Ovulation Induction
Sponsor: Merck KGaA, Darmstadt, Germany
Countries with listed sites: Switzerland
Registry dates and results: Start: 2007-12. Completion: 2009-03 (may be estimated). Results are posted in this registry.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

AS900672-Enriched 10 microgram (mcg) (drug) — also listed as: Hyperglycosylated r-hFSH
AS900672-Enriched 20 mcg (drug) — also listed as: Hyperglycosylated r-hFSH
AS900672-Enriched 30 mcg (drug) — also listed as: Hyperglycosylated r-hFSH
AS900672-Enriched 40 mcg (drug) — also listed as: Hyperglycosylated r-hFSH
Follitropin alfa 75 international unit (IU) (drug) — also listed as: Gonal-f®, Follicle stimulating hormone (FSH)
Recombinant human chorionic gonadotropin (r-hCG) (drug)

Where the study takes place — 1 listed sites

Merck Serono S.A.
Geneva, Switzerland
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)

ClinicalTrials.gov · NCT00505752 · Registry updated: 2014-02-13

Condition / research focus: Infertility
Sponsor: Merck KGaA, Darmstadt, Germany
Countries with listed sites: United States
Registry dates and results: Start: 2007-01. Completion: 2008-09 (may be estimated). Results are posted in this registry.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

AS900672-Enriched 50 microgram (mcg) (drug) — also listed as: Hyperglycosylated r-hFSH
AS900672-Enriched 100 mcg (drug) — also listed as: Hyperglycosylated r-hFSH
AS900672-Enriched 150 mcg (drug) — also listed as: Hyperglycosylated r-hFSH
Follitropin alfa 150 international unit (IU) (drug) — also listed as: Gonal-f®, Follicle stimulating hormone (FSH)
Recombinant human chorionic gonadotropin (r-hCG) (drug) — also listed as: Ovidrel®, Choriogonadotropin alfa

Where the study takes place — 1 listed sites

Local US Medical Information Office
Rockland, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

CONSORT Randomized Controlled Trial in Assisted Reproductive Technology

ClinicalTrials.gov · NCT00829244 · Registry updated: 2014-02-13

Condition / research focus: Infertility
Sponsor: Merck KGaA, Darmstadt, Germany
Countries with listed sites: Switzerland
Registry dates and results: Start: 2008-08. Completion: 2010-01 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GONAL f® prefilled pen (drug) — also listed as: Follitropin alfa, Recombinant human follicle stimulating hormone (r-hFSH), GONAL-f® Prefilled Pen
GONAL f® prefilled pen (drug) — also listed as: Follitropin alfa, r-hFSH, GONAL-f® Prefilled Pen

Where the study takes place — 1 listed sites

Research Site
Geneva, Switzerland
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2TerminatedINTERVENTIONAL

A Clinical Trial to Determine the Effect of Lutropin Alfa on Embryo Quality and Implantation Rate in Advanced Reproductive Age

ClinicalTrials.gov · NCT01075815 · Registry updated: 2014-02-13

Condition / research focus: Infertility; Ovulation Induction
Sponsor: Merck KGaA, Darmstadt, Germany
Countries with listed sites: Spain
Registry dates and results: Start: 2008-11. Completion: 2010-10 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Recombinant human luteinizing hormone (rhLH) (drug) — also listed as: Luveris®, Lutropin alfa
Recombinant follicle-stimulating hormone (rFSH) (drug)

Where the study takes place — 1 listed sites

FivMadrid, C/ Marqués de Urquijo, 26,
Madrid, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Recombinant Follicle Stimulating Hormone (FSH) (Gonal-f®): Use in Ovulation Induction

ClinicalTrials.gov · NCT01081626 · Registry updated: 2014-02-13

Condition / research focus: Ovulation Induction
Sponsor: Merck KGaA, Darmstadt, Germany
Countries with listed sites: Kuwait · Lebanon · Saudi Arabia
Registry dates and results: Start: 2009-03. Completion: 2011-03 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Recombinant FSH (follitropin alpha) (drug) — also listed as: Gonal-f®, Follitropin alpha

Where the study takes place — 3 listed sites

New Mowasat Hospital
As Sālimīyah, P.O.Box 6661, Kuwait
Site recruitment: Not reported
Mount Lebanon Hospital
Hazmiyeh, P.O.Box 470, Lebanon
Site recruitment: Not reported
King Abdel Aziz University Hospital
Jeddah, P.O.Box 80215, Saudi Arabia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART)

ClinicalTrials.gov · NCT01185704 · Registry updated: 2014-02-13

Condition / research focus: Polycystic Ovarian Syndrome
Sponsor: Merck KGaA, Darmstadt, Germany
Countries with listed sites: France
Registry dates and results: Start: 2008-11. Completion: 2012-02 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Cetrorelix acetate (drug) — also listed as: Cetrotide®
Cetrorelix acetate (drug) — also listed as: Cetrotide®
Recombinant Human Choriogonadotropin (r-hCG) (drug) — also listed as: Ovitrelle®
Recombinant human follicle stimulating hormone (r-hFSH) (drug)

Where the study takes place — 1 listed sites

Research Site
Toulouse, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Sequential Therapy for Hypogonadotropic Hypogonadism

ClinicalTrials.gov · NCT01403532 · Registry updated: 2014-02-11

Condition / research focus: Hypogonadotropic Hypogonadism; Kallmann Syndrome
Sponsor: Shanghai Jiao Tong University School of Medicine
Countries with listed sites: China
Registry dates and results: Start: 2009-09. Completion: 2012-12 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Traditional intervention for HH using HCG and FSH (drug) — also listed as: Tranditional
Sequential intervention for HH using HCG and FSH (drug) — also listed as: Sequential
Sequential intervention for HH using HCG and FSH plus zinc (drug) — also listed as: Sequential plus

Where the study takes place — 1 listed sites

Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Study to Evaluate Safety and Efficacy of Recombinant Human Luteinizing Hormone (r-hLH) Compared With Urinary Human Chorionic Gonadotrophin (u-hCG) to Trigger Ovulation in Infertile Women

ClinicalTrials.gov · NCT01735422 · Registry updated: 2014-02-04

Condition / research focus: Infertility
Sponsor: Merck KGaA, Darmstadt, Germany
Countries with listed sites: Canada
Registry dates and results: Start: 1999-12. Completion: 2001-07 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

r-hFSH (drug) — also listed as: Gonal-f®
r-hLH (drug) — also listed as: LHadi®
u-hCG (drug)

Where the study takes place — 1 listed sites

Royal University Hospital
Saskatoon, Saskatchewan, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-09 04:14 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Not applicableCompletedINTERVENTIONAL

Semi-quantitative Pregnancy Test to Monitor hCG Levels After Assisted Fertility Treatment

ClinicalTrials.gov · NCT01919502 · Registry updated: 2014-05-14

Condition / research focus: Embryo Transfer; Intrauterine Insemination (IUI)
Sponsor: Gynuity Health Projects
Countries with listed sites: United States
Registry dates and results: Start: 2013-10. Completion: 2014-04 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semi-quantitative urine pregnancy test (device) — also listed as: Quanti5 Multilevel hCG Pregnancy Test

Where the study takes place — 1 listed sites

Stanford University Medical Center
Palo Alto, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Effectiveness of Pregnancy Tests as an Assessment Tool to Identify Continuing Pregnancy

ClinicalTrials.gov · NCT01856777 · Registry updated: 2014-05-14

Condition / research focus: Medical Abortion
Sponsor: Gynuity Health Projects
Countries with listed sites: Vietnam
Registry dates and results: Start: 2013-06. Completion: 2014-02 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semi-quantitative panel test (device) — also listed as: dBest (AmeriTek, Seattle WA, USA)
High sensitivity urine pregnancy test (device) — also listed as: Quickstick one-step hCG Pregnancy Test, Phamatech, San Diego, CA, USA

Where the study takes place — 2 listed sites

Hocmon General District Hospital
Hochiminh City, Vietnam
Site recruitment: Not reported
Hungvuong Hospital
Hochiminh City, Vietnam
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Validation of the Respirio Flu Test for the Rapid Identification of Influenza A/B

ClinicalTrials.gov · NCT01431768 · Registry updated: 2014-04-30

Condition / research focus: Influenza
Sponsor: Respirio Pty Ltd
Countries with listed sites: Australia
Registry dates and results: Start: 2011-07. Completion: 2012-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Respirio Flu Test (device)

Where the study takes place — 2 listed sites

Taringa 7 Day Medical Practice
Brisbane, Queensland, Australia
Site recruitment: Not reported
Capalaba Medical Centre
Brisbane, Queensland, Australia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Comparing the Efficacy of Urinary and Recombinant Human Chorionic Gonadotropin (hCG) on Oocyte Maturity

ClinicalTrials.gov · NCT01507376 · Registry updated: 2014-04-25

Condition / research focus: In Vitro Fertilization
Sponsor: Royan Institute
Countries with listed sites: Iran
Registry dates and results: Start: 2010-10. Completion: 2013-06 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

recombinant hCG (drug)
recombinant hCG (drug)
urinary hCG (drug)

Where the study takes place — 1 listed sites

Royan Institute
Tehran, Iran
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Live Birth After Fresh Embryo Transfer Vs Frozen-thawed Embryo Transfer in Women With Polycystic Ovary Syndrome

ClinicalTrials.gov · NCT01841528 · Registry updated: 2014-04-16

Condition / research focus: Polycystic Ovary Syndrome; Infertility
Sponsor: Zi-jiang Chen
Countries with listed sites: China
Registry dates and results: Start: 2013-06. Completion: 2015-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

fresh embryo transfer (other)
frozen-thawed embryo transfer (other)

Where the study takes place — 14 listed sites

The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
Site recruitment: Not reported
The First Affiliated Hospital of Lanzhou University
Lanzhou, Gansu, China
Site recruitment: Not reported
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, China
Site recruitment: Not reported
The sixth Affiliated Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, China
Site recruitment: Not reported
Guangxi Maternal and Child Health Hospital
Nanning, Guangxi, China
Site recruitment: Not reported
Renmin Hospital of Wuhan University
Wuhan, Hubei, China
Site recruitment: Not reported
Jiangsu Province Hospital
Nanjing, Jiangsu, China
Site recruitment: Not reported
Jiangxi Maternal and Child Health Hospital
Nanchang, Jiangxi, China
Site recruitment: Not reported
Reproductive Medicine Center in Shenyang City
Shenyang, Liaoning, China
Site recruitment: Not reported
Reproductive medical hospital affiliated to Shandong University
Jinan, Shandong, China
Site recruitment: Not reported
Yuhuangding Hospital in Yantai
Yantai, Shandong, China
Site recruitment: Not reported
Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Shanxi Provincial Maternity and Children's Hospital
Xi’an, Shanxi, China
Site recruitment: Not reported
Sir Run Run Shaw Hospital
Hangzhou, Zhejiang, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

A Study to Compare the Safety and Efficacy of Cetrotide® 3 Milligram (mg) Versus Antagon™ in Women Undergoing Ovarian Stimulation

ClinicalTrials.gov · NCT00298025 · Registry updated: 2014-03-26

Condition / research focus: Infertile Women Undergoing Assisted Reproductive Technology (ART)
Sponsor: EMD Serono
Countries with listed sites: No country reported
Registry dates and results: Start: 2003-09. Completion: 2004-05 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Cetrotide® (drug) — also listed as: Cetrorelix acetate
Antagon ™ (drug) — also listed as: Ganirelix acetate
Recombinant human follicle stimulating hormone (r-hFSH) (drug) — also listed as: Gonal-f®
Human Menopausal Gonadotropin (hMG) (drug) — also listed as: Pergonal®
Recombinant Human Choriogonadotropin (r-hCG) (drug) — also listed as: Ovidrel®, Choriogonadotropin alfa

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase not reported / not applicableTerminatedOBSERVATIONAL

Predictive Factors of Ovarian Response in Ovulation Induction With Intrauterine Insemination of a Gonal-f Low-dose Regimen

ClinicalTrials.gov · NCT01100346 · Registry updated: 2014-03-18

Condition / research focus: Infertility
Sponsor: Merck KGaA, Darmstadt, Germany
Countries with listed sites: Taiwan
Registry dates and results: Start: 2010-01. Completion: 2010-09 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Gonal-f (Follitropin alpha) (drug) — also listed as: Gonal-f

Where the study takes place — 1 listed sites

Far Eastern Memorial Hospital, No.21 Nan-Ya S. Rd., Sec.2 Pan-Chiao
Taipei, Taiwan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Progesterone Serum Levels in Subfertile Female Patients Undergoing in Vitro Fertilisation (IVF)

ClinicalTrials.gov · NCT01225835 · Registry updated: 2014-03-14

Condition / research focus: Infertility
Sponsor: Ferring Pharmaceuticals
Countries with listed sites: Germany
Registry dates and results: Start: 2010-10. Completion: 2013-06 (may be estimated). Results are posted in this registry.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Menotrophin (drug) — also listed as: Menogon® HP
Follitrophin alpha (drug) — also listed as: Gonal-f®
Cetrorelix (drug) — also listed as: Cetrotide®, GnRH antagonist
Choriongonadotropin (drug) — also listed as: Brevactid®, human chorionic gonadotropin (hCG)
Progesterone (drug) — also listed as: Crinone®, intravaginal progesterone

Where the study takes place — 8 listed sites

Fertility Center Berlin
Berlin, Germany
Site recruitment: Not reported
Praxisklinik Sydow am Gendarmenmarkt
Berlin, Germany
Site recruitment: Not reported
Kinderwunschzentrum Dortmund
Dortmund, Germany
Site recruitment: Not reported
Universitätsklinikum Duesseldorf, Frauenklinik
Düsseldorf, Germany
Site recruitment: Not reported
Praxis für Kinderwunschbehandlung
Erlangen, Germany
Site recruitment: Not reported
NOVUM Zentrum
Essen, Germany
Site recruitment: Not reported
IVF Zentrum
Saar, Germany
Site recruitment: Not reported
Endokrinologikum Ulm
Ulm, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Efficacy and Safety Study of Topical Rapamycin Associated With Pulsed Dye Laser in Patients With Sturge-Weber Syndrome

ClinicalTrials.gov · NCT02080624 · Registry updated: 2014-03-06

Condition / research focus: Sturge- Weber Syndrome
Sponsor: Clinica Universidad de Navarra, Universidad de Navarra
Countries with listed sites: Spain
Registry dates and results: Start: 2011-01. Completion: 2012-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Drug: Topical Rapamycin (drug) — also listed as: topical rapamycin 1%

Where the study takes place — 1 listed sites

Clinica Universidad de Navarra
Pamplona, Navarre, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2TerminatedINTERVENTIONAL

A Phase II Study to Assess the Efficacy and Safety of Luveris® (Lutropin Alfa) in Mid Follicular Phase for Controlled Ovarian Stimulation (COS) in Advanced Reproductive Age

ClinicalTrials.gov · NCT01079949 · Registry updated: 2014-02-27

Condition / research focus: Infertility; Ovulation Induction
Sponsor: Merck KGaA, Darmstadt, Germany
Countries with listed sites: Spain
Registry dates and results: Start: 2007-11. Completion: 2010-10 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

r-hLH + r-hFSH (drug) — also listed as: Luveris®, Lutropin alfa
r-hFSH (drug)
Recombinant Human Choriogonadotropin (r-hCG) (drug) — also listed as: Ovitrelle®
GnRH antagonist (drug) — also listed as: Cetrotide®

Where the study takes place — 1 listed sites

Instituto Marqués
Barcelona, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Long Acting FSH Plus Antagonist Versus Daily FSH Plus Antagonist Versus Short Agonist Protocol in Poor Responders Undergoing IVF

ClinicalTrials.gov · NCT02070198 · Registry updated: 2014-02-25

Condition / research focus: Female Infertility; Poor Responder
Sponsor: Bioroma
Countries with listed sites: Italy
Registry dates and results: Start: 2013-12. Completion: 2014-12 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Long acting FSH and GnRH antagonist (drug)
Daily FSH and GnRH antagonist (drug)
Triptorelin and recombinant FSH (drug)

Where the study takes place — 1 listed sites

Bioroma
Rome, Italy, Italy
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Intrauterine Injection of HCG and Implantation Rate

ClinicalTrials.gov · NCT01933126 · Registry updated: 2014-02-19

Condition / research focus: Pregnancy Rate; Implantation Rate
Sponsor: Assaf-Harofeh Medical Center
Countries with listed sites: Israel
Registry dates and results: Start: 2013-08. Completion: 2014-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

HCG injection (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Assaf Harofeh Medical Center
Be’er Ya‘aqov, Zerifin, Israel
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2TerminatedINTERVENTIONAL

AS900672-Enriched in Ovulation Induction

ClinicalTrials.gov · NCT00553514 · Registry updated: 2014-02-13

Condition / research focus: Ovulation Induction
Sponsor: Merck KGaA, Darmstadt, Germany
Countries with listed sites: Switzerland
Registry dates and results: Start: 2007-12. Completion: 2009-03 (may be estimated). Results are posted in this registry.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

AS900672-Enriched 10 microgram (mcg) (drug) — also listed as: Hyperglycosylated r-hFSH
AS900672-Enriched 20 mcg (drug) — also listed as: Hyperglycosylated r-hFSH
AS900672-Enriched 30 mcg (drug) — also listed as: Hyperglycosylated r-hFSH
AS900672-Enriched 40 mcg (drug) — also listed as: Hyperglycosylated r-hFSH
Follitropin alfa 75 international unit (IU) (drug) — also listed as: Gonal-f®, Follicle stimulating hormone (FSH)
Recombinant human chorionic gonadotropin (r-hCG) (drug)

Where the study takes place — 1 listed sites

Merck Serono S.A.
Geneva, Switzerland
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)

ClinicalTrials.gov · NCT00505752 · Registry updated: 2014-02-13

Condition / research focus: Infertility
Sponsor: Merck KGaA, Darmstadt, Germany
Countries with listed sites: United States
Registry dates and results: Start: 2007-01. Completion: 2008-09 (may be estimated). Results are posted in this registry.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

AS900672-Enriched 50 microgram (mcg) (drug) — also listed as: Hyperglycosylated r-hFSH
AS900672-Enriched 100 mcg (drug) — also listed as: Hyperglycosylated r-hFSH
AS900672-Enriched 150 mcg (drug) — also listed as: Hyperglycosylated r-hFSH
Follitropin alfa 150 international unit (IU) (drug) — also listed as: Gonal-f®, Follicle stimulating hormone (FSH)
Recombinant human chorionic gonadotropin (r-hCG) (drug) — also listed as: Ovidrel®, Choriogonadotropin alfa

Where the study takes place — 1 listed sites

Local US Medical Information Office
Rockland, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

CONSORT Randomized Controlled Trial in Assisted Reproductive Technology

ClinicalTrials.gov · NCT00829244 · Registry updated: 2014-02-13

Condition / research focus: Infertility
Sponsor: Merck KGaA, Darmstadt, Germany
Countries with listed sites: Switzerland
Registry dates and results: Start: 2008-08. Completion: 2010-01 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GONAL f® prefilled pen (drug) — also listed as: Follitropin alfa, Recombinant human follicle stimulating hormone (r-hFSH), GONAL-f® Prefilled Pen
GONAL f® prefilled pen (drug) — also listed as: Follitropin alfa, r-hFSH, GONAL-f® Prefilled Pen

Where the study takes place — 1 listed sites

Research Site
Geneva, Switzerland
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2TerminatedINTERVENTIONAL

A Clinical Trial to Determine the Effect of Lutropin Alfa on Embryo Quality and Implantation Rate in Advanced Reproductive Age

ClinicalTrials.gov · NCT01075815 · Registry updated: 2014-02-13

Condition / research focus: Infertility; Ovulation Induction
Sponsor: Merck KGaA, Darmstadt, Germany
Countries with listed sites: Spain
Registry dates and results: Start: 2008-11. Completion: 2010-10 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Recombinant human luteinizing hormone (rhLH) (drug) — also listed as: Luveris®, Lutropin alfa
Recombinant follicle-stimulating hormone (rFSH) (drug)

Where the study takes place — 1 listed sites

FivMadrid, C/ Marqués de Urquijo, 26,
Madrid, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Recombinant Follicle Stimulating Hormone (FSH) (Gonal-f®): Use in Ovulation Induction

ClinicalTrials.gov · NCT01081626 · Registry updated: 2014-02-13

Condition / research focus: Ovulation Induction
Sponsor: Merck KGaA, Darmstadt, Germany
Countries with listed sites: Kuwait · Lebanon · Saudi Arabia
Registry dates and results: Start: 2009-03. Completion: 2011-03 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Recombinant FSH (follitropin alpha) (drug) — also listed as: Gonal-f®, Follitropin alpha

Where the study takes place — 3 listed sites

New Mowasat Hospital
As Sālimīyah, P.O.Box 6661, Kuwait
Site recruitment: Not reported
Mount Lebanon Hospital
Hazmiyeh, P.O.Box 470, Lebanon
Site recruitment: Not reported
King Abdel Aziz University Hospital
Jeddah, P.O.Box 80215, Saudi Arabia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART)

ClinicalTrials.gov · NCT01185704 · Registry updated: 2014-02-13

Condition / research focus: Polycystic Ovarian Syndrome
Sponsor: Merck KGaA, Darmstadt, Germany
Countries with listed sites: France
Registry dates and results: Start: 2008-11. Completion: 2012-02 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Cetrorelix acetate (drug) — also listed as: Cetrotide®
Cetrorelix acetate (drug) — also listed as: Cetrotide®
Recombinant Human Choriogonadotropin (r-hCG) (drug) — also listed as: Ovitrelle®
Recombinant human follicle stimulating hormone (r-hFSH) (drug)

Where the study takes place — 1 listed sites

Research Site
Toulouse, France
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Sequential Therapy for Hypogonadotropic Hypogonadism

ClinicalTrials.gov · NCT01403532 · Registry updated: 2014-02-11

Condition / research focus: Hypogonadotropic Hypogonadism; Kallmann Syndrome
Sponsor: Shanghai Jiao Tong University School of Medicine
Countries with listed sites: China
Registry dates and results: Start: 2009-09. Completion: 2012-12 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Traditional intervention for HH using HCG and FSH (drug) — also listed as: Tranditional
Sequential intervention for HH using HCG and FSH (drug) — also listed as: Sequential
Sequential intervention for HH using HCG and FSH plus zinc (drug) — also listed as: Sequential plus

Where the study takes place — 1 listed sites

Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Study to Evaluate Safety and Efficacy of Recombinant Human Luteinizing Hormone (r-hLH) Compared With Urinary Human Chorionic Gonadotrophin (u-hCG) to Trigger Ovulation in Infertile Women

ClinicalTrials.gov · NCT01735422 · Registry updated: 2014-02-04

Condition / research focus: Infertility
Sponsor: Merck KGaA, Darmstadt, Germany
Countries with listed sites: Canada
Registry dates and results: Start: 1999-12. Completion: 2001-07 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

r-hFSH (drug) — also listed as: Gonal-f®
r-hLH (drug) — also listed as: LHadi®
u-hCG (drug)

Where the study takes place — 1 listed sites

Royal University Hospital
Saskatoon, Saskatchewan, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →